TCRR | TCR2 Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.4800 - 1.4800
52 Week Range	0.8210 - 3.88
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	3,753,354
Average Volume	325,040
Shares Outstanding	39,261,700
Market Cap	58,107,316
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-02-14

Valuation
Profitability
Growth
Health
P/E Ratio	-0.35
Forward P/E Ratio	N/A
EPS	-4.20
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	58
Country	USA
Website	TCRR

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

TCRR's peers: ADCT, ADVM, AFMD, AGEN, AKRO, ALEC, ALXO, BDTX, CABA, CRMD, CRNX, DARE, DTIL, ETON, EWTX, FDMT, GOSS, IGMS, NKTX, PGEN, PLRX, PRLD, QSI, RNA, RVMD, SLDB, SRRK, STOK, SWTX, TNGX, YMAB

*Chart delayed

Analyzing fundamentals for TCRR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see TCRR Fundamentals page.

Watching at TCRR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TCRR Technicals page.